Drug Approval | December 01, 2023
Eugia Pharma receives USFDA approval for Budesonide Inhalation Suspension
The product is expected to be launched in FY25
The product is expected to be launched in FY25
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Decision on EU marketing authorisation expected for momelotinib by early 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The product will be manufactured at Lupin’s Nagpur facility in India
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Subscribe To Our Newsletter & Stay Updated
